Background: The safety and performance of the current Absorb Bioresorbable Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa Clara, CA) has been previously established in 101 patients from Cohort B of the First-in-Man ABSORB trial. At 48 months, the MACE rate in Cohort B was 10.1%, with no scaffold thrombosis reported. ABSORB EXTEND was initiated as a global continued access study (outside of the US) to expand experience with the Absorb BVS to different geographies. Additionally, patients were allowed to be treated for longer coronary lesions and smaller vessels than those in the Cohort B trial, using either longer scaffold lengths or planned overlap with the 2.5 and 3.0 mm Absorb BVS. Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study that enrolled 812 subjects at 58 sites. Included were patients with lesions 28 mm in length and reference vessel diameter of 2.0 -3.3 mm (as assessed by on-line QCA or IVUS). Treatment of a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel, was permitted. Results: Interim 24-month data in the first 250 ABSORB EXTEND study patients has been previously presented. Patients included 33% with unstable angina, 29% with prior MI and 27% with diabetes mellitus. The mean RVD was 2.61AE0.35 mm and mean lesion length was 11.61 mm. In these 250 patients, the hierarchical MACE, TVF and def/prob ST rates at 2 year were 7.3%, 8.1% and 0.8% respectively. Long-term, 36-month follow-up data will be presented for these patients and will provide substantial data on the long-term safety and performance of the Absorb BVS in a larger population of patients, including those with planned overlapping and dual vessel treatment. Furthermore, a propensity score matched comparison with Xience treated patients from the SPIRIT trials will be presented. Conclusions: Long-term outcomes in approximately 250 patients at 36 months (the largest patient cohort reported at this time point to date) from ABSORB EXTEND will provide further insight into the safety and performance of the Absorb BVS.
Background: Bioresorbable vascular scaffold (BVS) implantation has been suggested to induce a tissue response separating potentially thrombogenic plaque components from the lumen, thus 'sealing' the plaque. Attenuation is an optical property of tissues that can be measured in optical coherence tomography (OCT) images. High attenuation is associated with necrotic core or macrophages, whereas lower attenuation values correspond to more benign phenotypes. We analysed the attenuation properties of a segment treated with BVS 5 years post implantation. Methods: 8 of 14 living patients enrolled of the Thoraxcenter cohort of ABSORB A, underwent additional OCT follow-up, 5 years post BVS implantation. The 5year OCT images were examined with attenuation analysis. Attenuation was quantified at the treated segment circumferentially by custom-made software 1) at the entire depth of the plaque and 2) at a superficial signal-rich layer after manual segmentation. Results: The mean attenuation value within the 'sealing layer' was 1.77AE0.32mm-1 and the median was 1.28AE0.25mm-1. This value was higher within the entire 'neoplaque' (mean: 2.87AE0.54mm-1, median: 2.33AE0.49 mm-1, p< 0.001). Spread-out attenuation maps at different depths from the luminal surface are displayed in the Figure. The surface layers (first 200mm) had low attenuation, overlying high-attenuation areas located deeper in the plaque.
Conclusions: At long-term BVS follow-up, attenuation analysis confirms the finding in most cases of a superficial homogeneous layer with low attenuation, unlikely to contain high-risk wall components such as necrotic core and macrophages.
TCT-617
Short-and long-term safety evaluation of a novel bioresorbable scaffold in a miniature swine coronary artery model Kazuyuki Yahagi 1 , Erica Pacheco 1 , Masataka Nakano 1 , Fumiyuki Otsuka 1 , Kenichi Sakakura 1 , OSCAR D. SANCHEZ 1 , Elena Ladich 1 , Frank D. Kolodgie 1 , Antoine Lafont 2 , Michael Joner 1 , Renu Virmani 1 1 CVPath Institute, Inc., Gaithersburg, MD, 2 HEGP paris descartes university, Paris, France Background: Current bioresorbable scaffold technology has shown promising results in small-sized clinical studies. However, preclinical data addressing long-term vascular reactions remain limited. The aim of this study was to investigate vascular responses of a novel bioresorbable polymeric scaffold (BRS) (PLA; Arterial Remodeling Technologies, Paris, France) by histology and optical coherence tomography (OCT) compared with bare-metal stent (BMS; Vision, Abbott Vascular, Santa Clara, CA, USA) in porcine coronary arteries. Methods: A total of 107 devices (54 BRS and 53 BMS) were implanted in miniature swine coronary arteries and examined by OCT at follow-up of and all were examined by light microscopy at each time point. Results: Lumen area was significantly smaller in BRS than BMS at 30-, and 90-days. Although neointima area was increasing over time in BRS, lumen area also progressively increased after 90 days whereas in BMS luminal gain was not observed. Inflammation score was greater in BRS compared to BMS at 3-to 24-months. Peak degradation of stent struts was observed between 3 to 9 months. While BRS showed a significant positive correlation between lumen area and inflammation score from 1 to 9-months, a negative correlation was observed in BMS ( figure) .
Conclusions: This study shows positive remodeling of coronary vessels treated with BRS with increasing lumen area over time. Lumen area enlargement was associated with inflammation reaction during peak degradation. for 40% and C for 4%. In Group B2, late loss at 3 years was 0.29 AE 0.43mm, unchanged from 1 year (0.27AE 0.34mm) and vasomotion, as a response to nitroglycerine injection, was demonstrated. Quantitative IVUS results revealed mean scaffold area and mean lumen area enlargement between baseline and 3 years. The scaffold enlargement at 3 years was confirmed by OCT. At 3 years, the strut cores were still visible on OCT, which is in line with earlier pre-clinical data showing that the scaffold is biodegraded and replaced by provisional matrix at 3 years. Hypothetically, due to the integration process after bioresorption, further lumen enlargement as well as wall thinning could be expected at later time points. Clinical data up to 4 years showed an ID-MACE rate of 10.1% with no events of scaffold thrombosis. Conclusions: The long-term 5-year QCA and vasomotion results for Cohort B1 will be presented.
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